GALECTIN-3 LEVEL IN pATIENTS WITH mETAbOLIC SYNDROmE AND CORONARY HEART DISEASE

Abstract

Aim. To assess the level of galectin-3 in blood serum of patients with metabolic syndrome (MS), including comorbidity with coronary heart disease (CHD), for evaluation of its significance as fibrosis marker in MS.Material and methods. Totally, 43 MS patients studied with CHD signs, and 33 patients non-MS of comparable age, of those CHD was diagnosed in 17. Mean age in MS group was 62,7±10,3 y.o. at baseline, in controls (non-MS) — 60±14,7 y.o. Galectin-3 level was measured via immune-enzyme assay on “Platinum ELISA”.Results. Mean level of galectin-3 in MS group was significantly higher and reached 1,89±1,71 ng/mL, comparing to non-MS group — 1,03±0,22 ng/mL (р=0,006). There were positive correlations of galectin-3 and CHD functional class by NYHA (r=0,346, р=0,012): in absence of CHD signs galectin-3 level was 1,05±0,26 ng/mL; in CHD of 1 functional class (FC) — 1,06±0,18 ng/mL; 2 FC — 1,7±1,59 ng/mL; 3 FC — 2,15±1,85 ng/mL.Conclusion. The level of fibrosis marker galectin-3 are higher in MS patients than in non-MS, and in MS+CHD is higher than in those without this pathology. Finding of high level of galectin-3 in MS and CHD patients might witness on the severity of myocardial fibrosis, supporting prognosis.

Keywords

• galectin-3
• fibrosis marker
• coronary heart disease
• metabolic syndrome